Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTLM12X)

• DTT Name: Matrix metalloproteinase-2 (MMP-2) DTT Info
• Gene Name: MMP2

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Prinomastat	DM9HOKG	Lung cancer	2C25.0	Approved	[1]

4 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epigallocatechin gallate	DMCGWBJ	Hepatic fibrosis	DB93.0	Phase 3	[2]
Marimastat	DM6V34C	Pancreatic cancer	2C10	Phase 3	[3]
Metastat	DMTQ4PN	Acne vulgaris	ED80	Phase 1	[4]
Neovastat	DMXTYWJ	Non-small-cell lung cancer	2C25.Y	Phase 1	[5]

10 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID29130358-Compound-Figure10(2a)	DMFWXPS	N. A.	N. A.	Patented	[6]
PMID29130358-Compound-Figure11(3)	DMSME2B	N. A.	N. A.	Patented	[6]
PMID29130358-Compound-Figure13(4)	DMDFPIO	N. A.	N. A.	Patented	[6]
PMID29130358-Compound-Figure16(9a)	DMKX5R8	N. A.	N. A.	Patented	[6]
PMID29130358-Compound-Figure16(9b)	DMPAQLZ	N. A.	N. A.	Patented	[6]
PMID29130358-Compound-Figure16(9c)	DM0ZRI9	N. A.	N. A.	Patented	[6]
PMID29130358-Compound-Figure18(14)	DM7WXJ9	N. A.	N. A.	Patented	[6]
PMID29130358-Compound-Figure18(14a)	DMHIBTZ	N. A.	N. A.	Patented	[6]
PMID29130358-Compound-LonimacranthoideVII	DMOGIAU	N. A.	N. A.	Patented	[6]
PMID29130358-Compound-SB-3CT	DMC64XQ	N. A.	N. A.	Patented	[6]

10 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BMS 275291	DMKSFPE	Kaposi sarcoma	2B57	Discontinued in Phase 3	[7]
Tanomastat	DMVB9XC	Lung cancer	2C25.0	Discontinued in Phase 3	[8]
Galarubicin	DMTNYSF	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[9]
GM6001	DM7V9CT	Corneal ulcer	9A76	Discontinued in Phase 2	[10]
RS-130830	DMOTANY	Hepatitis C virus infection	1E51.1	Discontinued in Phase 2	[11]
BB-1101	DM7GH5Z	Multiple sclerosis	8A40	Terminated	[13]
BB-3644	DM7YRFE	Solid tumour/cancer	2A00-2F9Z	Terminated	[14]
CDP-845	DMGMS2D	Solid tumour/cancer	2A00-2F9Z	Terminated	[15]
L-696418	DMV785R	N. A.	N. A.	Terminated	[16]
SC-44463	DMBPNKT	N. A.	N. A.	Terminated	[17]

1 Preclinical Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RO-26-2853	DM3ZE5A	Solid tumour/cancer	2A00-2F9Z	Preclinical	[12]

30 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid	DMSN7GJ	Discovery agent	N.A.	Investigative	[18]
2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid	DMQAVM4	Discovery agent	N.A.	Investigative	[19]
2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide	DMCNV5J	Discovery agent	N.A.	Investigative	[20]
3-(4-(2-phenylethynyl)benzoyl)pentanoic acid	DMQDPHT	Discovery agent	N.A.	Investigative	[21]
3-(4-Phenylethynylbenzoyl)nonanoic acid	DMXL0J5	Discovery agent	N.A.	Investigative	[21]
4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid	DM6KIG0	Discovery agent	N.A.	Investigative	[21]
5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione	DM05OMF	Discovery agent	N.A.	Investigative	[22]
5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione	DMFAITE	Discovery agent	N.A.	Investigative	[22]
5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione	DMI2PXO	Discovery agent	N.A.	Investigative	[22]
5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione	DM4S86L	Discovery agent	N.A.	Investigative	[22]
Cis-2-aminocyclohexylcarbamoylphosphonic acid	DMF10WT	Discovery agent	N.A.	Investigative	[23]
Clinopodic acid C	DMS58P1	Discovery agent	N.A.	Investigative	[24]
Folate gamma-hydroxamic acid	DMJ4F3Q	Discovery agent	N.A.	Investigative	[25]
Folate gamma-L-proline-hydroxamic acid	DMH5SQV	Discovery agent	N.A.	Investigative	[25]
IK-862	DMJA4UE	Discovery agent	N.A.	Investigative	[26]
Lithospermic acid	DMPAKQV	Discovery agent	N.A.	Investigative	[24]
Methotrexate gamma-hydroxamic acid	DM8P526	Discovery agent	N.A.	Investigative	[25]
Methotrexate gamma-L-proline-hydroxamic acid	DMPYJLA	Discovery agent	N.A.	Investigative	[25]
MMI270	DM38N2K	Discovery agent	N.A.	Investigative	[27]
N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide	DM4VADN	Discovery agent	N.A.	Investigative	[20]
N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	DMWXUCT	Discovery agent	N.A.	Investigative	[28]
N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	DMA6EPH	Discovery agent	N.A.	Investigative	[28]
PD-169469	DMU3OR1	Discovery agent	N.A.	Investigative	[29]
PNU-107859	DMS5XRY	Discovery agent	N.A.	Investigative	[30]
Ro-37-9790	DM83QMZ	Discovery agent	N.A.	Investigative	[31]
Roche 28-2653	DMD4JHK	Discovery agent	N.A.	Investigative	[32]
SC-74020	DMNI91Z	Discovery agent	N.A.	Investigative	[33]
SR-973	DMU48OD	Discovery agent	N.A.	Investigative	[34]
UK-356618	DM02FGH	Discovery agent	N.A.	Investigative	[17]
[2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid	DM37C25	Discovery agent	N.A.	Investigative	[20]

References

• [1] AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
• [2] Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
• [3] Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
• [4] Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.
• [5] Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
• [6] Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
• [7] Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
• [8] Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer. Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:44-6.
• [9] Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix m... Biochem Pharmacol. 2005 Dec 19;71(1-2):21-31.
• [10] Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
• [11] Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
• [12] Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
• [13] Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8.
• [14] Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39.
• [15] Clinical potential of matrix metalloprotease inhibitors. Drugs R D. 1999 Feb;1(2):117-29.
• [16] Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995).
• [17] A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
• [18] The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3.
• [19] Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3096-100.
• [20] Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61.
• [21] Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8.
• [22] Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.
• [23] Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic mat... J Med Chem. 2008 Mar 13;51(5):1406-14.
• [24] Matrix metalloproteinase-2 inhibitors from Clinopodium chinense var. parviflorum. J Nat Prod. 2009 Aug;72(8):1379-84.
• [25] Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74.
• [26] Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.
• [27] Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. Bioorg Med Chem Lett. 1999 Jun 21;9(12):1691-6.
• [28] Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5.
• [29] Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J Med Chem. 2006 Feb 9;49(3):923-31.
• [30] A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics s... J Med Chem. 2004 Jun 3;47(12):3065-74.
• [31] 11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997).
• [32] The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene. 2002 Mar 27;21(13):2089-96.
• [33] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [34] Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.